Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.
The Biologics market has changed dramatically since the introduction of the Biologics Price Competition and Innovation Act in 2014 in the US. The act provides a pathway for similar biologics to make it to market safely, cost-effectively, and legally.
Chinese genome sequencing company BGI has been given the go-ahead to appeal an English High Court ruling in an ongoing lawsuit launched by competitor Illumina regarding its DNA sequencing patents.
Since the formalisation of the new Biologics Price Competition and Innovation Act framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.
Medical device maker Nevro has hit competitor Boston Scientific with a lawsuit for allegedly infringing patents that cover a spinal cord stimulation technology.
A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.
Innovation by medical and pharma sectors has increased over the past year in the wake of the pandemic, a new report by IP services company Clarivate has confirmed.
Bayer Healthcare is suing medical devices manufacturer Ecomed Solutions over allegedly patent-infringing syringes.
AbbVie and its Korean partner Medytox have settled a trade secret dispute with competitor Evolus over the sale of a rival botox competitor drug Jeuveau.
The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.